2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
2006
Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based Chemotherapy
Kelly M, O’Malley D, Hui P, McAlpine J, Yu H, Rutherford T, Azodi M, Schwartz P. Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based Chemotherapy. Obstetrical & Gynecological Survey 2006, 61: 27-29. DOI: 10.1097/01.ogx.0000193850.73725.34.Peer-Reviewed Original ResearchUterine papillary serous carcinomaStage IA patientsStage IB patientsPlatinum-based chemotherapyRecurrence of diseaseEndometrial aspiration biopsyResidual uterine diseaseStage IA diseaseDisease-free survivalPapillary serous carcinomaRisk of recurrenceIB patientsTreatment modalitiesAbdominopelvic radiationAdjuvant chemotherapyIA patientsSerous carcinomaIA diseaseAdjuvant therapyAdjuvant treatmentOverall survivalUterine carcinomaVaginal cuffUterine diseaseAspiration biopsy